Literature DB >> 8198911

Plasma concentration and protein binding of alfentanil during high-dose infusion for cardiac surgery.

M Hynynen1, M Hynninen, H Soini, P J Neuvonen, J Heinonen.   

Abstract

We have studied plasma protein binding of alfentanil in 10 patients given a mean total dose of 949 micrograms kg-1 as the principal anaesthetic agent for coronary artery bypass grafting. The mean unbound fraction of plasma alfentanil increased from 0.09 to 0.16 after administration of heparin and to 0.26 after beginning cardiopulmonary bypass (CPB). After CPB until the end of surgery, the unbound fraction decreased to 0.12. These changes in the unbound fraction were associated with significant changes in plasma total and unbound concentrations of alfentanil also. Within the first 1 min of CPB, total alfentanil concentration had decreased by more than the unbound concentration and the decrease observed in the latter disappeared rapidly. From induction of anaesthesia until awakening of the patient, plasma protein binding of alfentanil was related significantly (P = 0.0166) to the serum concentration of orosomucoid (alpha 1-acid glyco-protein).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198911     DOI: 10.1093/bja/72.5.571

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients.

Authors:  R S Miller; G M Peterson; F Abbott; I Maddocks; D Parker; S McLean
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

3.  Propofol sequestration within the extracorporeal circuit.

Authors:  M Hynynen; E Hammarén; P H Rosenberg
Journal:  Can J Anaesth       Date:  1994-07       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.